Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03055013
Recruitment Status : Recruiting
First Posted : February 16, 2017
Last Update Posted : October 15, 2019
Sponsor:
Collaborator:
Canadian Cancer Trials Group
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.

Condition or disease Intervention/treatment Phase
Metastatic Malignant Neoplasm in Lymph Node Metastatic Malignant Neoplasm in the Adrenal Gland Metastatic Malignant Neoplasm in the Lung Metastatic Malignant Neoplasm in the Pancreas Metastatic Malignant Neoplasm in the Skin Metastatic Malignant Neoplasm in the Soft Tissues Metastatic Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Stage II Renal Cell Cancer AJCC v7 Stage III Renal Cell Cancer AJCC v7 Unclassified Renal Cell Carcinoma Procedure: Conventional Surgery Biological: Nivolumab Other: Patient Observation Other: Quality-of-Life Assessment Other: Questionnaire Administration Phase 3

  Hide Detailed Description

Detailed Description:

PRIMARY OBJECTIVES:

I. To compare recurrence-free survival (RFS) between patients with renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone.

SECONDARY OBJECTIVES:

I. To evaluate for differences in recurrence-free survival associated with perioperative nivolumab compared to surgery alone among the subset of patients with clear cell histology.

II. To compare the overall survival between the two arms. III. To describe the safety and tolerability of perioperative nivolumab.

CORRELATIVE OBJECTIVES:

I. To correlate the primary tumor's expression of programmed cell death 1 ligand 1 (PD-L1) with outcome.

II. To correlate the expression of PD-L1 on tumor tissue at recurrence with outcome.

III. To archive images for central confirmation of recurrence and for future correlative work with American College of Radiology Imaging Network (ACRIN), including markers predicting outcome or response.

IV. To prospectively collect tumor and biologic specimens (e.g., serum, peripheral blood mononuclear cells [PBMCs]) for future correlative studies.

V. To characterize the pharmacokinetics of nivolumab and explore exposure response relationships with respect to safety and efficacy.

VI. To characterize the immunogenicity of nivolumab.

QUALITY OF LIFE OBJECTIVES:

I. To evaluate differences in change from baseline in patient-reported symptoms and toxicities among patients randomized to treatment with nivolumab compared to surgery alone.

OTHER EXPLORATORY OBJECTIVES:

I. To explore descriptively the efficacy of treatment with nivolumab in patients with non-clear cell (including unclassified) histologies.

II. To characterize the effects of nivolumab on bone metabolism and bone density.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive nivolumab intravenously (IV) over 30-60 minutes on day 1. Treatment repeats every 14 days for 2 cycles. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab over 30-60 IV on day 1. Treatment repeats every 14 days for 6 cycles, and then every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients enrolled after Amendment 4 receive nivolumab IV over 30-60 minutes on day 1. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 4 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo partial or radical nephrectomy within 8 weeks after registration followed by observation.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and every 12 months for 5 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 805 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Actual Study Start Date : February 2, 2017
Estimated Primary Completion Date : November 30, 2023
Estimated Study Completion Date : November 30, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Arm I (nivolumab, nephrectomy)

Patients receive nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 2 cycles. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab over 30-60 IV on day 1. Treatment repeats every 14 days for 6 cycles, and then every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients enrolled after Amendment 4 receive nivolumab IV over 30-60 minutes on day 1. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 4 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity.

Procedure: Conventional Surgery
Undergo nephrectomy

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Active Comparator: Arm II (nephrectomy)
ARM II: Patients undergo partial or radical nephrectomy within 8 weeks after registration followed by observation.
Procedure: Conventional Surgery
Undergo nephrectomy

Other: Patient Observation
Undergo observation
Other Names:
  • Active Surveillance
  • deferred therapy
  • expectant management
  • Observation
  • watchful waiting

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Recurrence-free survival (RFS) [ Time Frame: Time from randomization to disease recurrence or death from any cause, assessed up to 10 years ]
    Will be assessed among all randomized patients using a stratified log rank test, with nominal one-sided type I error of 2.5%. The type I error will be adjusted for interim analyses.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]
  2. RFS among patients with clear cell cancer [ Time Frame: Up to 10 years ]
    The stratified logrank test will be used.

  3. Incidence of toxicity [ Time Frame: Up to 10 years ]
    Graded per Common Criteria for Adverse Events (CTCAE) version (v)4.0. (Starting April 1, 2018, Cancer Therapy Evaluation Program Adverse Event Reporting System [CTEP-AERS] reporting will use CTCAE v5). Adverse events will be described separately for patients treated on each arm to evaluate safety and tolerability.


Other Outcome Measures:
  1. Primary tumor's expression of PD-L1 [ Time Frame: Baseline to up to 10 years ]
    The percentage of cells exhibiting cell-surface staining for PD-L1 will be scored. PD-L1 positivity will be defined per specimen by a 5% expression threshold. Additional analyses will assess the 1% and 10% threshold levels. Information with respect to the relative abundance and location (peritumoral/intratumoral) of immune cell (macrophage and lymphocyte) PD-L1 staining will be captured. The expression-by-treatment interaction will be tested using a proportional hazards model. McNemar's Test will be used to explore categorical changes within each treatment group.

  2. Expression of PD-L1 on tumor tissue at recurrence [ Time Frame: Up to 10 years ]
  3. Pharmacokinetic analysis of nivolumab [ Time Frame: On day 1 of courses 1-3, 5, 7 and the first 2 follow-up visits ]
    Serum concentration analyses for nivolumab will be performed by validated bio-analytical methods for nivolumab.

  4. Change in patient-reported symptoms and toxicities [ Time Frame: Baseline to up to 10 years ]
    Using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN/FACT) Kidney Symptom Index-19 (NFKSI-19) and items from the PRO-CTCAE pool of items measuring patient-reported toxicity. We will describe the severity, interference, and (as appropriate) frequency rates, along with response rates at each time point. Change in symptoms will be tested using a two-sided Wilcoxon rank sum test with Type I error of 3%. Change in physical function will be tested using a two-sided Wilcoxon rank sum test with Type I error of 1%. Changes in NFKSI-19 and PROMIS Physical Function scores from baseline to pre-nephrectomy among patients randomized to nivolumab and will be explored using a Wilcoxon signed rank test. Differences in scores post-nephrectomy between the arms will be described and tested using a Wilcoxon rank-sum test. Differences in the pattern of change over time in NFKSI-19 and PROMIS Physical Function scores will be examined using mixed effects models.

  5. Absolute T cell clonotype abundance [ Time Frame: Up to 10 years ]
    Will be determined by assessing the number of unique clonotypes identified. The data will be summarized descriptively and graphically.

  6. Change in T cell repertoire [ Time Frame: From diagnosis to on therapy or to time of recurrence, assessed up to 10 years ]
    Morisita's distance will be used as utilized by Cha and colleagues. Morisita's distance ranges from 0-1. Zero indicates minimal change in T cell repertoire (TCR) repertoire size (number of unique clonotypes) and 1 indicates maximal change after treatment.

  7. T cell receptor (TCR) diversity using change in repertoire size per patient [ Time Frame: Baseline to up to 10 years ]
    The top 25% of unique clonotypes will be identified by sorting for clone frequency. Fold change after recurrence will be measured and plotted on a logarithmic scale.

  8. Change in cytokine levels in patients randomized to the nivolumab arm [ Time Frame: Baseline to up to 10 years ]
    Differences in RFS between patients with and without robust CD8 infiltration will be explored. A Cox proportional hazards model will be used to test the interaction between treatment and cytokine changes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ELIGIBILITY CRITERIA FOR PREREGISTRATION (STEP 0):
  • Patients with a renal mass consistent with a clinical stage >= T2Nx renal cell carcinoma (RCC) or TanyN+ RCC for which radical or partial nephrectomy is planned
  • Patients must have no clinical or radiological evidence of distant metastases (M0) unless the presumed M1 disease can be resected/definitively treated (e.g., thermal ablation, stereotactic radiation) at the same time or within a 12 week window from the date of the initial procedure such that the patient is considered "no evidence of disease" (M1 NED)

    • Permitted sites of oligo-metastases: lung, adrenal, nodes, pancreas, soft tissue or skin; liver or bone metastases are not permitted
    • No more than 3 metastases are permitted and all must be able to be removed or definitively treated within 12 weeks of the primary tumor resection
  • If histological confirmation of RCC has not been done within 12 months prior to pre-registration (Step 0), patient must be willing to undergo a core biopsy for this purpose if randomized to Arm H

    • NOTE: This can be a (1) standard of care diagnostic biopsy or (2) a research biopsy following assignment to Arm H or a planned metastasectomy before or after randomization; if the biopsy performed following pre-registration (Step 0) clearly demonstrates a benign condition, oncocytoma or a different type of cancer that is not RCC, the patient is not eligible for registration (Step 1); a non-diagnostic biopsy is considered a good faith effort and does not need to be repeated unless deemed clinically necessary by the treating investigator
    • NOTE: Patients randomized to Arm O (Observation) are permitted to register to Step 1 (Arm B) immediately following pre-registration assignment to Arm O, regardless of whether or not they have had a standard of care diagnostic biopsy
  • No prior systemic or local anti-cancer therapy for the current RCC is permitted

    • Partial nephrectomy for prior RCC
    • Metastasectomy for the current RCC diagnosis is not allowed unless performed to render patient NED (in addition to the planned nephrectomy) within 6 months of the current diagnosis
    • Radiation therapyto the bilateral kidney or any distant metastatic sites, is not allowed unless administered to render patient NED within 6 months of the current diagnosis
    • Current or past antineoplastic systemic therapies for RCC are not allowed: i.e., chemotherapy, hormonal therapy, immunotherapy, or standard or investigational agents for treatment of RCC
    • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1
  • Patient must have no prior history of RCC that was resected with curative intent within the past 5 years

    • Patients with a prior RCC that was treated > 5 years before, are eligible if the current tumor is consistent with a new primary in the opinion of the treating investigator
    • Patients with bilateral synchronous RCCs are eligible if they can be resected or definitively treated at the same time or within a 12 week window from time of initial nephrectomy (partial or radical) or procedure and maintain adequate residual renal function; the patient is not eligible if both kidneys are completely removed and subsequent hemodialysis is required

      • Permitted forms of local therapy for second tumor:

        • Partial or radical nephrectomy
        • If tumor is =< 3cm: thermal ablation (e.g., radiofrequency ablation, cryoablation or stereotactic radiosurgery)
  • Patients cannot have concurrent malignancies, with the following exceptions:

    • Adequately treated basal cell or squamous cell skin cancer
    • In situ cervical cancer

      • A history of superficial Ta urothelial cancer is permitted (as long as not currently undergoing treatment) whereas T1 or greater disease is excluded if < 3 years from diagnosis; concurrent persistent disease is not permitted
      • Adequately treated stage I or II cancer from which the patient is currently in complete remission
      • Any other cancer and stage from which the patient has been disease-free for at least 3 years prior to the time of pre-registration and as long as they are not receiving any current treatment (e.g. adjuvant or maintenance systemic or local therapy)
      • Concurrent low risk prostate cancer on active surveillance
  • No active known or suspected autoimmune disease; the following autoimmune disorders are permitted: patients with vitiligo, type I diabetes mellitus, controlled/stable hypothyroidism due to autoimmune or non-autoimmune conditions (hormone replacement is allowed), psoriasis not requiring systemic treatment, or other conditions not expected to recur
  • No ongoing condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications with the exceptions outlined below; no treatment with other immunosuppressive agents within 14 days prior to the first dose of study drug with the following exceptions:

    • Topical, ocular, intra-articular, intranasal, inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone or the equivalent are permitted in the absence of active autoimmune disease
    • A brief (less than 3 weeks) course of corticosteroids (any amount) for prophylaxis (for example: contrast dye allergy) or for treatment of non-autoimmune conditions (for example: nausea, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
  • No uncontrolled adrenal insufficiency
  • No known chronic active liver disease or evidence of acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • No serious intercurrent illness, including ongoing or active infection requiring parenteral antibodies
  • No known evidence of human immunodeficiency virus (HIV) infection, since the effects of nivolumab on anti-retroviral therapy have not been studied
  • No known medical condition (e.g. a condition associated with uncontrolled diarrhea such as ulcerative colitis or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or interfere with the interpretation of safety results
  • No major surgery within 28 days prior to randomization
  • No patients currently enrolled in other clinical trials testing a therapeutic intervention
  • No history of severe hypersensitivity to a monoclonal antibody
  • Ability to understand and the willingness to sign a written informed consent document
  • ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1):
  • Patients must meet all Step 0 eligibility criteria at the time of their registration to Step 1
  • In patients randomized to Arm H, core tumor biopsy must demonstrate RCC of any histology, including sarcomatoid, unclassified, or "unknown histology" (if preoperative biopsy was uninformative)

    • NOTE: A non-diagnostic biopsy is considered a good faith effort and does not need to be repeated unless deemed clinically necessary by the treating investigator
  • Women must not be pregnant or breast-feeding, as the effects of nivolumab on the developing human fetus or in the nursing infant are unknown; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point 2) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use accepted and effective method(s) of contraception, or to abstain from sexual intercourse for the duration of their participation in the study; women of childbearing potential must use adequate methods to avoid pregnancy for 23 weeks after the last dose of nivolumab; sexually active males must use adequate methods to avoid pregnancy for 31 weeks after the last dose of nivolumab
  • White blood cells >= 2000/uL (within 8 weeks of registration)
  • Absolute neutrophil count (ANC) >= 1,500/mm^3 (within 8 weeks of registration)
  • Platelet count >= 100,000/mm^3 (within 8 weeks of registration)
  • Hemoglobin >= 9.0 g/dL (within 8 weeks of registration)
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 x ULN) (within 8 weeks of registration)
  • Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 x ULN) (within 8 weeks of registration)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (within 8 weeks of registration)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03055013


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
University of Arizona Cancer Center at Saint Joseph's Recruiting
Phoenix, Arizona, United States, 85004
Contact: Site Public Contact    602-406-8222      
Principal Investigator: Jue Wang         
Banner University Medical Center - Tucson Recruiting
Tucson, Arizona, United States, 85719
Contact: Site Public Contact       aselegue@email.arizona.edu   
Principal Investigator: Benjamin R. Lee         
University of Arizona Cancer Center-North Campus Recruiting
Tucson, Arizona, United States, 85719
Contact: Site Public Contact    800-327-2873      
Principal Investigator: Benjamin R. Lee         
United States, California
Kaiser Permanente-Anaheim Recruiting
Anaheim, California, United States, 92806
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Sutter Auburn Faith Hospital Suspended
Auburn, California, United States, 95602
AIS Cancer Center at San Joaquin Community Hospital Recruiting
Bakersfield, California, United States, 93301
Contact: Site Public Contact    661-323-4673      
Principal Investigator: Primo N. Lara         
Kaiser Permanente-Baldwin Park Recruiting
Baldwin Park, California, United States, 91706
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Kaiser Permanente-Bellflower Recruiting
Bellflower, California, United States, 90706
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Alta Bates Summit Medical Center-Herrick Campus Recruiting
Berkeley, California, United States, 94704
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Ari D. Baron         
City of Hope Comprehensive Cancer Center Recruiting
Duarte, California, United States, 91010
Contact: Site Public Contact    800-826-4673    becomingapatient@coh.org   
Principal Investigator: Sumanta K. Pal         
Kaiser Permanente-Fontana Recruiting
Fontana, California, United States, 92335
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Kaiser Permanente - Harbor City Recruiting
Harbor City, California, United States, 90710
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Kaiser Permanente-Irvine Recruiting
Irvine, California, United States, 92618
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Site Public Contact    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: Rana R. McKay         
Kaiser Permanente Los Angeles Medical Center Recruiting
Los Angeles, California, United States, 90027
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
USC / Norris Comprehensive Cancer Center Active, not recruiting
Los Angeles, California, United States, 90033
Kaiser Permanente-Cadillac Recruiting
Los Angeles, California, United States, 90034
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Site Public Contact    310-423-8965      
Principal Investigator: Timothy J. Daskivich         
UCLA / Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: Site Public Contact    888-798-0719      
Principal Investigator: Brian Shuch         
Fremont - Rideout Cancer Center Recruiting
Marysville, California, United States, 95901
Contact: Site Public Contact    530-749-4400      
Principal Investigator: Primo N. Lara         
Palo Alto Medical Foundation-Camino Division Suspended
Mountain View, California, United States, 94040
Kaiser Permanente-Oakland Recruiting
Oakland, California, United States, 94611
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Kaiser Permanente-Ontario Recruiting
Ontario, California, United States, 91761
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Palo Alto Medical Foundation Health Care Recruiting
Palo Alto, California, United States, 94301
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Ari D. Baron         
Kaiser Permanente - Panorama City Recruiting
Panorama City, California, United States, 91402
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Eisenhower Medical Center Active, not recruiting
Rancho Mirage, California, United States, 92270
Kaiser Permanente-Riverside Recruiting
Riverside, California, United States, 92505
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Kaiser Permanente-Roseville Recruiting
Roseville, California, United States, 95661
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Sutter Roseville Medical Center Suspended
Roseville, California, United States, 95661
Kaiser Permanente Downtown Commons Recruiting
Sacramento, California, United States, 95814
Contact: Site Public Contact    877-642-4691    kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Sutter Medical Center Sacramento Suspended
Sacramento, California, United States, 95816
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Site Public Contact    916-734-3089      
Principal Investigator: Primo N. Lara         
Kaiser Permanente - Sacramento Suspended
Sacramento, California, United States, 95825
Kaiser Permanente-San Diego Zion Recruiting
San Diego, California, United States, 92120
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
California Pacific Medical Center-Pacific Campus Recruiting
San Francisco, California, United States, 94115
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Ari D. Baron         
Kaiser Permanente-San Francisco Recruiting
San Francisco, California, United States, 94115
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Kaiser Permanente-Santa Teresa-San Jose Recruiting
San Jose, California, United States, 95119
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Kaiser Permanente San Leandro Recruiting
San Leandro, California, United States, 94577
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Pacific Central Coast Health Center-San Luis Obispo Active, not recruiting
San Luis Obispo, California, United States, 93401
Kaiser Permanente-San Marcos Recruiting
San Marcos, California, United States, 92078
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
Kaiser Permanente Medical Center - Santa Clara Recruiting
Santa Clara, California, United States, 95051
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Palo Alto Medical Foundation-Santa Cruz Recruiting
Santa Cruz, California, United States, 95065
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Ari D. Baron         
Kaiser Permanente-South San Francisco Recruiting
South San Francisco, California, United States, 94080
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Palo Alto Medical Foundation-Sunnyvale Recruiting
Sunnyvale, California, United States, 94086
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Ari D. Baron         
Gene Upshaw Memorial Tahoe Forest Cancer Center Recruiting
Truckee, California, United States, 96161
Contact: Site Public Contact    530-582-6450      
Principal Investigator: Primo N. Lara         
Kaiser Permanente-Vallejo Recruiting
Vallejo, California, United States, 94589
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Sutter Solano Medical Center/Cancer Center Recruiting
Vallejo, California, United States, 94589
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Ari D. Baron         
Kaiser Permanente-Walnut Creek Recruiting
Walnut Creek, California, United States, 94596
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Jennifer M. Suga         
Presbyterian Intercommunity Hospital Recruiting
Whittier, California, United States, 90602
Contact: Site Public Contact    562-698-0811      
Principal Investigator: Dustin E. Stevenson         
Kaiser Permanente-Woodland Hills Recruiting
Woodland Hills, California, United States, 91367
Contact: Site Public Contact    800-398-3996    clinical.trials@kp.org   
Principal Investigator: Helen H. Moon         
United States, Colorado
UCHealth Memorial Hospital Central Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Site Public Contact    719-365-2406      
Principal Investigator: Geetika Srivastava         
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Site Public Contact    970-297-6150      
Principal Investigator: Geetika Srivastava         
United States, Connecticut
Hartford Hospital Recruiting
Hartford, Connecticut, United States, 06102
Contact: Site Public Contact    860-545-5363      
Principal Investigator: Jeffrey M. Kamradt         
Midstate Medical Center Recruiting
Meriden, Connecticut, United States, 06451
Contact: Site Public Contact    866-662-5678      
Principal Investigator: Jeffrey M. Kamradt         
The Hospital of Central Connecticut Recruiting
New Britain, Connecticut, United States, 06050
Contact: Site Public Contact    860-224-5660      
Principal Investigator: Jeffrey M. Kamradt         
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Site Public Contact    203-785-5702    canceranswers@yale.edu   
Principal Investigator: Michael E. Hurwitz         
Eastern Connecticut Hematology and Oncology Associates Recruiting
Norwich, Connecticut, United States, 06360
Contact: Site Public Contact    860-886-8362      
Principal Investigator: Dennis E. Slater         
United States, District of Columbia
MedStar Washington Hospital Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Site Public Contact    202-877-8839      
Principal Investigator: Ross E. Krasnow         
George Washington University Medical Center Recruiting
Washington, District of Columbia, United States, 20037
Contact: Site Public Contact    202-741-2981      
Principal Investigator: Jianqing Lin         
United States, Florida
Holy Cross Hospital Recruiting
Fort Lauderdale, Florida, United States, 33308
Contact: Site Public Contact    954-267-7750      
Principal Investigator: Leonard J. Seigel         
Baptist MD Anderson Cancer Center Active, not recruiting
Jacksonville, Florida, United States, 32207
The Watson Clinic Recruiting
Lakeland, Florida, United States, 33805
Contact: Site Public Contact    863-680-7780      
Principal Investigator: Neeharika Srivastava Makani         
United States, Georgia
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Site Public Contact    404-778-1868      
Principal Investigator: Viraj Master         
Atlanta VA Medical Center Recruiting
Decatur, Georgia, United States, 30033
Contact: Site Public Contact    404-321-6111 ext 7632      
Principal Investigator: Wayne B. Harris         
United States, Hawaii
Pali Momi Medical Center Recruiting
'Aiea, Hawaii, United States, 96701
Contact: Site Public Contact    808-486-6000      
Principal Investigator: Charles O. Kim         
Hawaii Cancer Care Inc-POB II Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact    808-524-6115      
Principal Investigator: Charles O. Kim         
Hawaii Oncology Inc-POB I Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact    808-532-0315      
Principal Investigator: Charles O. Kim         
Queen's Medical Center Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact    808-545-8548      
Principal Investigator: Charles O. Kim         
Straub Clinic and Hospital Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact    808-522-4333      
Principal Investigator: Charles O. Kim         
Hawaii Oncology Inc-Kuakini Recruiting
Honolulu, Hawaii, United States, 96817
Contact: Site Public Contact    808-531-8521      
Principal Investigator: Charles O. Kim         
United States, Idaho
Saint Luke's Mountain States Tumor Institute Suspended
Boise, Idaho, United States, 83712
Saint Luke's Mountain States Tumor Institute - Fruitland Suspended
Fruitland, Idaho, United States, 83619
Saint Luke's Mountain States Tumor Institute - Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
Saint Luke's Mountain States Tumor Institute - Nampa Suspended
Nampa, Idaho, United States, 83686
Saint Luke's Mountain States Tumor Institute-Twin Falls Suspended
Twin Falls, Idaho, United States, 83301
United States, Illinois
Illinois CancerCare-Bloomington Recruiting
Bloomington, Illinois, United States, 61704
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Canton Recruiting
Canton, Illinois, United States, 61520
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Carthage Recruiting
Carthage, Illinois, United States, 62321
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Site Public Contact    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jeffrey A. Sosman         
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-942-5498    clinical_trials@rush.edu   
Principal Investigator: Timothy M. Kuzel         
University of Chicago Comprehensive Cancer Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Site Public Contact    773-702-8222    cancerclinicaltrials@bsd.uchicago.edu   
Principal Investigator: Walter M. Stadler         
Carle on Vermilion Recruiting
Danville, Illinois, United States, 61832
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Cancer Care Specialists of Illinois - Decatur Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Effingham Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Elmhurst Memorial Hospital Recruiting
Elmhurst, Illinois, United States, 60126
Contact: Site Public Contact    630-758-5460    Jrohde@emhc.org   
Principal Investigator: Brian C. Myre         
Illinois CancerCare-Eureka Recruiting
Eureka, Illinois, United States, 61530
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Galesburg Recruiting
Galesburg, Illinois, United States, 61401
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Northwestern Medicine Cancer Center Delnor Recruiting
Geneva, Illinois, United States, 60134
Contact: Site Public Contact    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Michael Kahn         
Illinois CancerCare-Kewanee Clinic Recruiting
Kewanee, Illinois, United States, 61443
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Macomb Recruiting
Macomb, Illinois, United States, 61455
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Carle Physician Group-Mattoon/Charleston Recruiting
Mattoon, Illinois, United States, 61938
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Site Public Contact    708-226-4357      
Principal Investigator: Stephanie A. Berg         
Edward Hospital/Cancer Center Recruiting
Naperville, Illinois, United States, 60540
Contact: Site Public Contact    630-646-6075      
Principal Investigator: Brian C. Myre         
Illinois CancerCare-Ottawa Clinic Recruiting
Ottawa, Illinois, United States, 61350
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Pekin Recruiting
Pekin, Illinois, United States, 61554
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Peru Recruiting
Peru, Illinois, United States, 61354
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Edward Hospital/Cancer Center?Plainfield Recruiting
Plainfield, Illinois, United States, 60585
Contact: Site Public Contact    630-646-6075    Cancerresearch@edward.org   
Principal Investigator: Brian C. Myre         
Illinois CancerCare-Princeton Recruiting
Princeton, Illinois, United States, 61356
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Springfield Clinic Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact    800-444-7541      
Principal Investigator: Bryan A. Faller         
Cancer Care Specialists of Illinois-Swansea Recruiting
Swansea, Illinois, United States, 62226
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
The Carle Foundation Hospital Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Vamsi K. Vasireddy         
Northwestern Medicine Cancer Center Warrenville Recruiting
Warrenville, Illinois, United States, 60555
Contact: Site Public Contact    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Michael Kahn         
United States, Indiana
Parkview Regional Medical Center Recruiting
Fort Wayne, Indiana, United States, 46845
Contact: Site Public Contact    877-784-4673      
Principal Investigator: Zhentao Zhang         
Indiana University/Melvin and Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Site Public Contact    317-278-5632    iutrials@iu.edu   
Principal Investigator: Roberto Pili         
Sidney and Lois Eskenazi Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Site Public Contact    317-278-5632    iutrials@iu.edu   
Principal Investigator: Roberto Pili         
Franciscan Health Indianapolis Recruiting
Indianapolis, Indiana, United States, 46237
Contact: Site Public Contact    317-528-7060      
Principal Investigator: Sarah Ali         
Franciscan Health Mooresville Recruiting
Mooresville, Indiana, United States, 46158
Contact: Site Public Contact    317-834-3603      
Principal Investigator: Sarah Ali         
Reid Health Recruiting
Richmond, Indiana, United States, 47374
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
United States, Iowa
Mary Greeley Medical Center Recruiting
Ames, Iowa, United States, 50010
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC - Ames Recruiting
Ames, Iowa, United States, 50010
Contact: Site Public Contact    515-239-4734    ksoder@mcfarlandclinic.com   
Principal Investigator: Debra M. Prow         
McFarland Clinic PC-Boone Recruiting
Boone, Iowa, United States, 50036
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
Medical Oncology and Hematology Associates-West Des Moines Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Cancer Center-West Lakes Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Medical Oncology and Hematology Associates-Laurel Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Medical Center - Des Moines Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
McFarland Clinic PC-Trinity Cancer Center Recruiting
Fort Dodge, Iowa, United States, 50501
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC-Jefferson Recruiting
Jefferson, Iowa, United States, 50129
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
McFarland Clinic PC-Marshalltown Recruiting
Marshalltown, Iowa, United States, 50158
Contact: Site Public Contact    515-956-4132      
Principal Investigator: Debra M. Prow         
Mercy Medical Center-West Lakes Recruiting
West Des Moines, Iowa, United States, 50266
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Kansas
Hays Medical Center Recruiting
Hays, Kansas, United States, 67601
Contact: Site Public Contact    785-623-5774      
Principal Investigator: Elizabeth Wulff-Burchfield         
University of Kansas Cancer Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Elizabeth Wulff-Burchfield         
Olathe Medical Center Recruiting
Olathe, Kansas, United States, 66061
Contact: Site Public Contact    913-791-3500    Jeni.wakefield@olathehealth.org   
Principal Investigator: Elizabeth Wulff-Burchfield         
University of Kansas Cancer Center-Overland Park Recruiting
Overland Park, Kansas, United States, 66210
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Elizabeth Wulff-Burchfield         
Via Christi Hospital-Pittsburg Recruiting
Pittsburg, Kansas, United States, 66762
Contact: Site Public Contact    620-235-7900      
Principal Investigator: Elizabeth Wulff-Burchfield         
Salina Regional Health Center Recruiting
Salina, Kansas, United States, 67401
Contact: Site Public Contact    785-452-7038    kkavoura@srhc.com   
Principal Investigator: Elizabeth Wulff-Burchfield         
Saint Francis Hospital and Medical Center - Topeka Recruiting
Topeka, Kansas, United States, 66606
Contact: Site Public Contact    785-295-8000      
Principal Investigator: Elizabeth Wulff-Burchfield         
University of Kansas Hospital-Westwood Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Elizabeth Wulff-Burchfield         
United States, Kentucky
University of Kentucky/Markey Cancer Center Recruiting
Lexington, Kentucky, United States, 40536
Contact: Site Public Contact    859-257-3379      
Principal Investigator: Peng Wang         
United States, Louisiana
LSU Health Baton Rouge-North Clinic Recruiting
Baton Rouge, Louisiana, United States, 70805
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Louisiana Hematology Oncology Associates LLC Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Mary Bird Perkins Cancer Center Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Our Lady of the Lake Physicians Group - Medical Oncology Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Northshore Oncology Associates-Covington Recruiting
Covington, Louisiana, United States, 70433
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Oncology Center of The South Incorporated Suspended
Houma, Louisiana, United States, 70360
East Jefferson General Hospital Recruiting
Metairie, Louisiana, United States, 70006
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
LSU Healthcare Network / Metairie Multi-Specialty Clinic Recruiting
Metairie, Louisiana, United States, 70006
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
Louisiana State University Health Science Center Suspended
New Orleans, Louisiana, United States, 70112
Tulane University Health Sciences Center Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Site Public Contact    504-988-6121      
Principal Investigator: Hana F. Safah         
Ochsner Medical Center Jefferson Active, not recruiting
New Orleans, Louisiana, United States, 70121
Louisiana State University Health Sciences Center Shreveport Active, not recruiting
Shreveport, Louisiana, United States, 71103
United States, Maine
Harold Alfond Center for Cancer Care Recruiting
Augusta, Maine, United States, 04330
Contact: Site Public Contact    207-626-4855      
Principal Investigator: Peter Rubin         
Eastern Maine Medical Center Recruiting
Bangor, Maine, United States, 04401
Contact: Site Public Contact    207-973-4274      
Principal Investigator: Sarah J. Sinclair         
Waldo County General Hospital Recruiting
Belfast, Maine, United States, 04915
Contact: Site Public Contact    207-338-2500      
Principal Investigator: Peter Rubin         
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford Recruiting
Biddeford, Maine, United States, 04005
Contact: Site Public Contact       LLemire@mmc.org   
Principal Investigator: Peter Rubin         
Lafayette Family Cancer Center-EMMC Recruiting
Brewer, Maine, United States, 04412
Contact: Site Public Contact    800-987-3005      
Principal Investigator: Sarah J. Sinclair         
Penobscot Bay Medical Center Recruiting
Rockport, Maine, United States, 04856
Contact: Site Public Contact    207-396-8670    ClinicalResearch@mmc.org   
Principal Investigator: Peter Rubin         
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford Recruiting
Sanford, Maine, United States, 04073
Contact: Site Public Contact       LLemire@mmc.org   
Principal Investigator: Peter Rubin         
Maine Medical Partners - South Portland Recruiting
South Portland, Maine, United States, 04106
Contact: Site Public Contact    207-396-8670    ClinicalResearch@mmc.org   
Principal Investigator: Peter Rubin         
United States, Maryland
Greater Baltimore Medical Center Recruiting
Baltimore, Maryland, United States, 21204
Contact: Site Public Contact    443-849-3706      
Principal Investigator: Ari H. Elman         
Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting
Baltimore, Maryland, United States, 21287
Contact: Site Public Contact    410-955-8804    jhcccro@jhmi.edu   
Principal Investigator: Michael A. Carducci         
United States, Massachusetts
Beverly Hospital Recruiting
Beverly, Massachusetts, United States, 01915
Contact: Site Public Contact    978-922-3000 ext 2405      
Principal Investigator: Krishna S. Gunturu         
Massachusetts General Hospital Cancer Center Recruiting
Boston, Massachusetts, United States, 02114
Contact: Site Public Contact    877-726-5130      
Principal Investigator: Lauren C. Harshman         
Brigham and Women's Hospital Suspended
Boston, Massachusetts, United States, 02115
Boston Medical Center Recruiting
Boston, Massachusetts, United States, 02118
Contact: Site Public Contact    617-638-8265      
Principal Investigator: Gretchen A. Gignac         
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Site Public Contact    617-667-9925      
Principal Investigator: Lauren C. Harshman         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Site Public Contact    877-442-3324      
Principal Investigator: Lauren C. Harshman         
Lahey Hospital and Medical Center Recruiting
Burlington, Massachusetts, United States, 01805
Contact: Site Public Contact    781-744-3421    cancerclinicaltrials@lahey.org   
Principal Investigator: Krishna S. Gunturu         
Simonds-Sinon Regional Cancer Center Active, not recruiting
Fitchburg, Massachusetts, United States, 01420
Winchester Hospital Recruiting
Winchester, Massachusetts, United States, 01890
Contact: Site Public Contact    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Krishna S. Gunturu         
UMass Memorial Medical Center - University Campus Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Site Public Contact    508-856-3216    cancer.research@umassmed.edu   
Principal Investigator: Kriti Mittal         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
University of Michigan Comprehensive Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Site Public Contact    800-865-1125      
Principal Investigator: Ajjai S. Alva         
Saint Joseph Mercy Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Joseph Mercy Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Joseph Mercy Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Wayne State University/Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Ulka N. Vaishampayan         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Weisberg Cancer Treatment Center Suspended
Farmington Hills, Michigan, United States, 48334
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
William Beaumont Hospital-Royal Oak Recruiting
Royal Oak, Michigan, United States, 48073
Contact: Site Public Contact    248-551-7695      
Principal Investigator: Sugandh D. Shetty         
William Beaumont Hospital - Troy Recruiting
Troy, Michigan, United States, 48085
Contact: Site Public Contact    248-551-7695      
Principal Investigator: Sugandh D. Shetty         
United States, Minnesota
Minneapolis VA Medical Center Active, not recruiting
Minneapolis, Minnesota, United States, 55417
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Brian A. Costello         
Coborn Cancer Center at Saint Cloud Hospital Recruiting
Saint Cloud, Minnesota, United States, 56303
Contact: Site Public Contact    877-229-4907    coborncancercenter@centracare.com   
Principal Investigator: Donald J. Jurgens         
United States, Mississippi
Gulfport Memorial Hospital Recruiting
Gulfport, Mississippi, United States, 39502
Contact: Site Public Contact    504-210-3539    emede1@lsuhsc.edu   
Principal Investigator: Scott E. Delacroix         
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: Site Public Contact    601-815-6700      
Principal Investigator: John C. Henegan         
United States, Missouri
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-334-2230    sfmc@sfmc.net   
Principal Investigator: Bryan A. Faller         
University of Missouri - Ellis Fischel Recruiting
Columbia, Missouri, United States, 65212
Contact: Site Public Contact    573-882-7440      
Principal Investigator: Katie S. Murray         
Siteman Cancer Center at West County Hospital Active, not recruiting
Creve Coeur, Missouri, United States, 63141
Truman Medical Center Recruiting
Kansas City, Missouri, United States, 64108
Contact: Site Public Contact    816-404-4375      
Principal Investigator: Elizabeth Wulff-Burchfield         
The University of Kansas Cancer Center-North Recruiting
Kansas City, Missouri, United States, 64154
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Elizabeth Wulff-Burchfield         
The University of Kansas Cancer Center-Lee's Summit Recruiting
Lee's Summit, Missouri, United States, 64064
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Elizabeth Wulff-Burchfield         
Washington University School of Medicine Active, not recruiting
Saint Louis, Missouri, United States, 63110
Siteman Cancer Center at Saint Peters Hospital Active, not recruiting
Saint Peters, Missouri, United States, 63376
United States, Montana
Bozeman Deaconess Hospital Recruiting
Bozeman, Montana, United States, 59715
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
United States, Nebraska
CHI Health Saint Francis Recruiting
Grand Island, Nebraska, United States, 68803
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Site Public Contact    402-354-5144      
Principal Investigator: Ralph J. Hauke         
United States, Nevada
OptumCare Cancer Care at Seven Hills Recruiting
Henderson, Nevada, United States, 89052
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at Oakey Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Town Center Recruiting
Las Vegas, Nevada, United States, 89144
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
OptumCare Cancer Care at Fort Apache Recruiting
Las Vegas, Nevada, United States, 89148
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Central Valley Recruiting
Las Vegas, Nevada, United States, 89169
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
University Cancer Center Suspended
Las Vegas, Nevada, United States, 89169
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
United States, New Jersey
Englewood Hospital and Medical Center Recruiting
Englewood, New Jersey, United States, 07631
Contact: Site Public Contact    201-894-3456      
Principal Investigator: Mazyar Ghanaat         
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Site Public Contact    201-996-2879      
Principal Investigator: Robert S. Alter         
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Suspended
New Brunswick, New Jersey, United States, 08903
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Site Public Contact    732-235-8675      
Principal Investigator: Eric A. Singer         
Robert Wood Johnson University Hospital Somerset Recruiting
Somerville, New Jersey, United States, 08876
Contact: Site Public Contact    908-685-2481      
Principal Investigator: Dhiren S. Dave         
United States, New York
Montefiore Medical Center-Einstein Campus Recruiting
Bronx, New York, United States, 10461
Contact: Site Public Contact    718-379-6866    aaraiza@montefiore.org   
Principal Investigator: Benjamin A. Gartrell         
Montefiore Medical Center-Weiler Hospital Recruiting
Bronx, New York, United States, 10461
Contact: Site Public Contact    718-379-6866    aaraiza@montefiore.org   
Principal Investigator: Benjamin A. Gartrell         
Montefiore Medical Center - Moses Campus Recruiting
Bronx, New York, United States, 10467
Contact: Site Public Contact    718-379-6866    aaraiza@montefiore.org   
Principal Investigator: Benjamin A. Gartrell         
James J Peters VA Medical Center Recruiting
Bronx, New York, United States, 10468
Contact: Site Public Contact    718-584-9000    kl2965@cumc.columbia.edu   
Principal Investigator: Yeun-Hee A. Park         
Glens Falls Hospital Recruiting
Glens Falls, New York, United States, 12801
Contact: Site Public Contact    518-926-6700      
Principal Investigator: Scott D. Perrapato         
Northwell Health/Center for Advanced Medicine Recruiting
Lake Success, New York, United States, 11042
Contact: Site Public Contact    516-734-8896      
Principal Investigator: Thomas P. Bradley         
Long Island Jewish Medical Center Suspended
New Hyde Park, New York, United States, 11040
NYP/Weill Cornell Medical Center Suspended
New York, New York, United States, 10065
State University of New York Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Site Public Contact    315-464-5476      
Principal Investigator: Gennady Bratslavsky         
Dickstein Cancer Treatment Center Recruiting
White Plains, New York, United States, 10601
Contact: Site Public Contact    914-849-7582    mcortese@wphospital.org   
Principal Investigator: Dan Costin         
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Site Public Contact    877-668-0683    cancerclinicaltrials@med.unc.edu   
Principal Investigator: Tracy L. Rose         
Southeastern Medical Oncology Center-Clinton Suspended
Clinton, North Carolina, United States, 28328
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Site Public Contact    888-275-3853      
Principal Investigator: Jeffrey Crawford         
Southeastern Medical Oncology Center-Goldsboro Suspended
Goldsboro, North Carolina, United States, 27534
Wayne Memorial Hospital Active, not recruiting
Goldsboro, North Carolina, United States, 27534
Onslow Memorial Hospital Active, not recruiting
Jacksonville, North Carolina, United States, 28546
Southeastern Medical Oncology Center-Jacksonville Suspended
Jacksonville, North Carolina, United States, 28546
Vidant Oncology-Kenansville Recruiting
Kenansville, North Carolina, United States, 28349
Contact: Site Public Contact    252-559-2201    Carla.Zimmerman@vidanthealth.com   
Principal Investigator: Misbah U. Qadir         
Vidant Oncology-Kinston Recruiting
Kinston, North Carolina, United States, 28501
Contact: Site Public Contact    252-559-2201    Carla.Zimmerman@vidanthealth.com   
Principal Investigator: Misbah U. Qadir         
Vidant Oncology-Richlands Recruiting
Richlands, North Carolina, United States, 28574
Contact: Site Public Contact    252-559-2201    Carla.Zimmerman@vidanthealth.com   
Principal Investigator: Misbah U. Qadir         
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Site Public Contact    336-713-6771      
Principal Investigator: Michael M. Goodman         
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Sanford Broadway Medical Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Sanford Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-234-6161    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
United States, Ohio
Dayton Physicians LLC-Miami Valley South Recruiting
Centerville, Ohio, United States, 45459
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
University of Cincinnati/Barrett Cancer Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Site Public Contact    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Abhinav Sidana         
Good Samaritan Hospital - Cincinnati Suspended
Cincinnati, Ohio, United States, 45220
Bethesda North Hospital Suspended
Cincinnati, Ohio, United States, 45242
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Christopher J. Hoimes         
Kettering Medical Center Recruiting
Kettering, Ohio, United States, 45429
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Toledo Clinic Cancer Centers-Toledo Recruiting
Toledo, Ohio, United States, 43623
Contact: Site Public Contact    800-444-3561      
Principal Investigator: Rex B. Mowat         
University Pointe Suspended
West Chester, Ohio, United States, 45069
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Brian W. Cross         
Mercy Hospital Oklahoma City Recruiting
Oklahoma City, Oklahoma, United States, 73120
Contact: Site Public Contact    405-752-3402      
Principal Investigator: Jay W. Carlson         
United States, Oregon
Providence Oncology and Hematology Care Southeast Suspended
Clackamas, Oregon, United States, 97015
Providence Newberg Medical Center Suspended
Newberg, Oregon, United States, 97132
Providence Willamette Falls Medical Center Suspended
Oregon City, Oregon, United States, 97045
Providence Portland Medical Center Suspended
Portland, Oregon, United States, 97213
Providence Saint Vincent Medical Center Suspended
Portland, Oregon, United States, 97225
Kaiser Permanente Northwest Active, not recruiting
Portland, Oregon, United States, 97227
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Site Public Contact    503-494-1080    trials@ohsu.edu   
Principal Investigator: Christopher W. Ryan         
United States, Pennsylvania
Lehigh Valley Hospital-Cedar Crest Recruiting
Allentown, Pennsylvania, United States, 18103
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Lehigh Valley Hospital - Muhlenberg Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Heinric Williams         
Penn State Milton S Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033-0850
Contact: Site Public Contact    717-531-3779    CTO@hmc.psu.edu   
Principal Investigator: Monika Joshi         
University of Pennsylvania/Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Site Public Contact    800-474-9892      
Principal Investigator: Vivek K. Narayan         
University of Pittsburgh Cancer Institute (UPCI) Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Site Public Contact    412-647-8073      
Principal Investigator: Leonard J. Appleman         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Site Public Contact    610-988-9323      
Principal Investigator: Terrence P. Cescon         
UPMC Susquehanna Suspended
Williamsport, Pennsylvania, United States, 17701
United States, Rhode Island
Rhode Island Hospital Recruiting
Providence, Rhode Island, United States, 02903
Contact: Site Public Contact    401-444-1488      
Principal Investigator: Anthony E. Mega         
Miriam Hospital Suspended
Providence, Rhode Island, United States, 02906
United States, South Carolina
Medical University of South Carolina Active, not recruiting
Charleston, South Carolina, United States, 29425
Prisma Health Cancer Institute - Laurens Suspended
Clinton, South Carolina, United States, 29325
Prisma Health Cancer Institute - Easley Recruiting
Easley, South Carolina, United States, 29640
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Gibbs Cancer Center-Gaffney Recruiting
Gaffney, South Carolina, United States, 29341
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Michael Humeniuk         
Saint Francis Hospital Recruiting
Greenville, South Carolina, United States, 29601
Contact: Site Public Contact    864-603-6213    meissa_beckman@bshsi.org   
Principal Investigator: Robert D. Siegel         
Prisma Health Cancer Institute - Butternut Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Saint Francis Cancer Center Recruiting
Greenville, South Carolina, United States, 29607
Contact: Site Public Contact    864-603-6213    meissa_beckman@bshsi.org   
Principal Investigator: Robert D. Siegel         
Prisma Health Cancer Institute - Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Gibbs Cancer Center-Pelham Recruiting
Greer, South Carolina, United States, 29651
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Michael Humeniuk         
Prisma Health Cancer Institute - Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Spartanburg Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Michael Humeniuk         
Prisma Health Cancer Institute - Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
United States, Tennessee
Meharry Medical College Active, not recruiting
Nashville, Tennessee, United States, 37208
Vanderbilt University/Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Site Public Contact    800-811-8480      
Principal Investigator: Nancy B. Davis         
United States, Texas
UT Southwestern/Simmons Cancer Center-Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Site Public Contact    214-648-7097    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Vitaly Margulis         
UT Southwestern/Simmons Cancer Center-Fort Worth Recruiting
Fort Worth, Texas, United States, 76104
Contact: Site Public Contact    214-648-7097    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Vitaly Margulis         
University of Texas Medical Branch Active, not recruiting
Galveston, Texas, United States, 77555-0565
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Site Public Contact    713-798-1354    burton@bcm.edu   
Principal Investigator: Aihua E. Yen         
Ben Taub General Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Site Public Contact    713-873-2000      
Principal Investigator: Aihua E. Yen         
UTMB Cancer Center at Victory Lakes Active, not recruiting
League City, Texas, United States, 77573
UT Southwestern Clinical Center at Richardson/Plano Recruiting
Richardson, Texas, United States, 75080
Contact: Site Public Contact    972-669-7044    Suzanne.cole@utsouthwestern.edu   
Principal Investigator: Vitaly Margulis         
University of Texas Health Science Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Site Public Contact    210-450-3800    phoresearchoffice@uthscsa.edu   
Principal Investigator: Michael A. Liss         
United States, Utah
Farmington Health Center Recruiting
Farmington, Utah, United States, 84025
Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu   
Principal Investigator: Brock O'Neil         
Huntsman Cancer Institute/University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu   
Principal Investigator: Brock O'Neil         
South Jordan Health Center Suspended
South Jordan, Utah, United States, 84009
United States, Vermont
Central Vermont Medical Center/National Life Cancer Treatment Recruiting
Berlin, Vermont, United States, 05602
Contact: Site Public Contact    802-225-5400      
Principal Investigator: Scott D. Perrapato         
University of Vermont Medical Center Recruiting
Burlington, Vermont, United States, 05401
Contact: Site Public Contact    802-656-4101    rpo@uvm.edu   
Principal Investigator: Scott D. Perrapato         
University of Vermont and State Agricultural College Recruiting
Burlington, Vermont, United States, 05405
Contact: Site Public Contact    802-656-8990    rpo@uvm.edu   
Principal Investigator: Scott D. Perrapato         
United States, Virginia
University of Virginia Cancer Center Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Site Public Contact    434-243-6303    PAS9E@virginia.edu   
Principal Investigator: Robert Dreicer         
Sovah Health Martinsville Recruiting
Martinsville, Virginia, United States, 24115
Contact: Site Public Contact    276-666-7489    sharon.hubbard@lpnt.net   
Principal Investigator: Mohammed Saad         
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Site Public Contact    804-628-1939    mwellons@vcu.edu   
Principal Investigator: Asit K. Paul         
United States, Washington
Harrison HealthPartners Hematology and Oncology-Bremerton Recruiting
Bremerton, Washington, United States, 98310
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Wisconsin
Langlade Hospital and Cancer Center Recruiting
Antigo, Wisconsin, United States, 54409
Contact: Site Public Contact    715-623-9869    Juli.Alford@aspirus.org   
Principal Investigator: Harish G. Ahuja         
Aurora Cancer Care-Southern Lakes VLCC Recruiting
Burlington, Wisconsin, United States, 53105
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Marshfield Medical Center-EC Cancer Center Suspended
Eau Claire, Wisconsin, United States, 54701
Aurora Health Center-Fond du Lac Recruiting
Fond Du Lac, Wisconsin, United States, 54937
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Aurora Health Care Germantown Health Center Recruiting
Germantown, Wisconsin, United States, 53022
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Aurora Cancer Care-Grafton Recruiting
Grafton, Wisconsin, United States, 53024
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
UW Cancer Center Johnson Creek Recruiting
Johnson Creek, Wisconsin, United States, 53038
Contact: Site Public Contact    920-699-3500    lynda.persico@uwmf.wisc.edu   
Principal Investigator: Hamid Emamekhoo         
Aurora Cancer Care-Kenosha South Recruiting
Kenosha, Wisconsin, United States, 53142
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Site Public Contact    800-622-8922      
Principal Investigator: Hamid Emamekhoo         
Aurora Bay Area Medical Group-Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Marshfield Medical Center-Marshfield Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Demet Gokalp Yasar         
Aurora Cancer Care-Milwaukee Recruiting
Milwaukee, Wisconsin, United States, 53209
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Aurora Saint Luke's Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Site Public Contact    414-805-3666      
Principal Investigator: Deepak Kilari         
Aurora Sinai Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53233
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Marshfield Clinic-Minocqua Center Recruiting
Minocqua, Wisconsin, United States, 54548
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Demet Gokalp Yasar         
ProHealth D N Greenwald Center Recruiting
Mukwonago, Wisconsin, United States, 53149
Contact: Site Public Contact       research.institute@phci.org   
Principal Investigator: Timothy R. Wassenaar         
ProHealth Oconomowoc Memorial Hospital Recruiting
Oconomowoc, Wisconsin, United States, 53066
Contact: Site Public Contact    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
Vince Lombardi Cancer Clinic - Oshkosh Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Aurora Cancer Care-Racine Recruiting
Racine, Wisconsin, United States, 53406
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Marshfield Medical Center-Rice Lake Recruiting
Rice Lake, Wisconsin, United States, 54868
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Demet Gokalp Yasar         
Vince Lombardi Cancer Clinic-Sheboygan Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Marshfield Clinic Stevens Point Center Recruiting
Stevens Point, Wisconsin, United States, 54482
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Demet Gokalp Yasar         
Aurora Medical Center in Summit Recruiting
Summit, Wisconsin, United States, 53066
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Vince Lombardi Cancer Clinic-Two Rivers Recruiting
Two Rivers, Wisconsin, United States, 54241
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
ProHealth Waukesha Memorial Hospital Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Site Public Contact    262-928-7632      
Principal Investigator: Timothy R. Wassenaar         
UW Cancer Center at ProHealth Care Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Site Public Contact    262-928-5539    Chanda.miller@phci.org   
Principal Investigator: Timothy R. Wassenaar         
Aspirus Regional Cancer Center Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Site Public Contact    877-405-6866      
Principal Investigator: Harish G. Ahuja         
Marshfield Clinic-Wausau Center Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Demet Gokalp Yasar         
Aurora Cancer Care-Milwaukee West Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Aurora West Allis Medical Center Recruiting
West Allis, Wisconsin, United States, 53227
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Antony Ruggeri         
Marshfield Clinic - Weston Center Recruiting
Weston, Wisconsin, United States, 54476
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Demet Gokalp Yasar         
Aspirus UW Cancer Center Recruiting
Wisconsin Rapids, Wisconsin, United States, 54494
Contact: Site Public Contact    715-422-7718      
Principal Investigator: Harish G. Ahuja         
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Site Public Contact    403-521-3433      
Principal Investigator: Daniel Y. Heng         
Canada, Ontario
London Regional Cancer Program Recruiting
London, Ontario, Canada, N6A 4L6
Contact: Site Public Contact    519-685-8600      
Principal Investigator: Nicholas E. Power         
University Health Network-Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Site Public Contact    416-946-4501    clinical.trials@uhn.on.ca   
Principal Investigator: Antonio Finelli         
Windsor Regional Cancer Centre Recruiting
Windsor, Ontario, Canada, N8W 2X3
Contact: Site Public Contact    519-253-5253      
Principal Investigator: Sindu M. Kanjeekal         
Canada, Quebec
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Site Public Contact    819-820-6480    crcinformation.chus@ssss.gouv.qc.ca   
Principal Investigator: Michel Pavic         
Israel
Rambam Medical Center Recruiting
Haifa, Israel, 31096
Contact: Site Public Contact    972-4-8541737    y_rozen@rambam.health.gov.il   
Principal Investigator: Avivit Peer         
Shaare Zedek Medical Center Recruiting
Jerusalem, Israel, 91031
Contact: Site Public Contact    972-2-6666507      
Principal Investigator: Suliman Boulos         
Sponsors and Collaborators
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Investigators
Layout table for investigator information
Principal Investigator: Lauren C Harshman ECOG-ACRIN Cancer Research Group

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03055013     History of Changes
Other Study ID Numbers: NCI-2016-00326
NCI-2016-00326 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
EA8143
EA8143 ( Other Identifier: ECOG-ACRIN Cancer Research Group )
EA8143 ( Other Identifier: CTEP )
U10CA180820 ( U.S. NIH Grant/Contract )
First Posted: February 16, 2017    Key Record Dates
Last Update Posted: October 15, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Second Primary
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents